|
variable
|
category
|
PFS
|
OS
|
|---|
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
|---|
|
Smoking history
|
ever-smokers vs. never smoker
|
1.9(1.31–2.76)
|
0.001
|
2.206(1.43–3.40)
|
< 0.001
|
|
Smoking dosage
|
never smoker (PY = 0, Ref.)
|
1
| |
1
| |
|
0 < PY ≤10
|
0.84(0.45–1.55)
|
0.08
|
0.96(0.41–2.25)
|
0.93
|
|
11~ 30 PY
|
2.95(1.76–4.94)
|
< 0.001
|
2.29(1.29–4.05)
|
0.004
|
|
> 30 PY
|
8.33(4.18–16.75)
|
< 0.001
|
4.91(2.66–9.06)
|
< 0.001
|
|
11~ 30 PY vs. > 30 PY
|
2.97(1.35–6.56)
|
0.007
|
2.22(1.08–4.57)
|
0.03
|
|
Age
|
> 60 vs. ≤ 60 years
|
1.05(0.72–1.53)
|
0.78
|
0.99(0.64–1.53)
|
0.98
|
|
Sex
|
Male vs. female
|
1.39(0.78–1.62)
|
0.084
|
1.91(1.238–2.947)
|
0.003
|
|
ECOG PS
|
≥ 2 vs 0–1
|
1.76(0.99–3.12)
|
0.05
|
3.12(1.73–5.62)
|
< 0.001
|
|
Stage
|
IV vs. recurrent or III
|
1.23(1.03–1.46)
|
0.02
|
1.4(1.1–1.9)
|
0.02
|
|
Type of EGFR mutation
|
19 del vs. 21 L858R
|
1.2(0.81–1.7)
|
0.36
|
0.66(0.38–1.15)
|
0.15
|
|
Brain metastasis
| |
1.9(1.3–2.9)
|
0.001
|
2.54(1.46–4.41)
|
0.001
|
|
Line of targeted therapy
|
≥2nd line vs. 1st
|
1.15(0.80–1.64)
|
0.439
|
1.92(1.25–2.93)
|
< 0.001
|
|
Histopathology
|
High vs. low to moderate grade adenocarcinoma
|
1.17(0.81–1.69)
|
0.39
|
0.91(0.51–1.65)
|
0.78
|
|
Type of EGFR-TKI
| |
0.95(0.75–1.18)
|
0.63
|
1.2 (0.53–2.69)
|
0.66
|
- Abbreviation: HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status
- EGFR epidermal growth factor receptor
- Hazard ratios and p values are adjusted for patients’ age (≥60 years vs. < 60 years), sex (female vs. male), ECOG status (PS status 0–1 vs. PS status 2–4), initial tumor stage (stage IV vs. III or recurrent), and line of EGFR-TKI (≥2nd vs. 1st line [Ref.]) in Cox-proportional hazard model
